BiondVax today obtained Israeli Ministry of Health approval for a further clinical trial of the company's universal flu vaccine. 60 people will participate in the Phase I/II clinical trial, which is an expansion of the current trial that includes 24 people. The vaccine is designed to offer general protection against the flu, as opposed to specific strains of the disease.
With flu vaccines attracting much attention in recent months, shares in Ness Ziona-based BiondVax Pharmaceuticals Ltd. (TASE:BNDX) have risen 1,100% in the past five months.
BiondVax expects to receive the results of the initial trial during the fourth quarter of 2009, and to receive the results of the expanded trial in the first quarter of 2010.
People in the new trial will receive vaccine dosage of the universal flu vaccine twice, in two shots three weeks apart. Two weeks after the second vaccination, they will receive a shot of the commercial vaccine for the current flu season.
BiondVax's share rose 8.4% today to NIS 4.65, giving a market cap of NIS 118 million.
Published by Globes [online], Israel business news - www.globes-online.com - on September 7, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009